Brought to you by 
Clovis, Genentech study rociletinib/atezolizumab combination; assumed terminated
06 Oct 2021
Executive Summary
Clovis Oncology Inc. and Genentech Inc. agreed to study a combination of the former's rociletinib and latter's atezolizumab in a Phase Ib/II trial in advanced or metastatic EGFR-mutant-positive non-small cell lung cancer (NSCLC).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Clovis, Genentech study rociletinib/atezolizumab combination; assumed terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice